iBio (NASDAQ:IBIO) & Whitehawk Therapeutics (NASDAQ:WHWK) Head to Head Contrast

iBio (NASDAQ:IBIO) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Earnings and Valuation

This table compares iBio and Whitehawk Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$100,000.00	645.84	-$33.04 million	($0.34)	-3.82
Whitehawk Therapeutics	$7.14 million	36.97	-$20.60 million	($1.12)	-4.13

Whitehawk Therapeutics has higher revenue and earnings than iBio. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

7.9% of iBio shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 2.8% of iBio shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

iBio has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for iBio and Whitehawk Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1	0	4	3	3.12
Whitehawk Therapeutics	1	1	6	0	2.62

iBio currently has a consensus target price of $5.00, suggesting a potential upside of 284.62%. Whitehawk Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 77.11%. Given iBio’s stronger consensus rating and higher probable upside, equities analysts clearly believe iBio is more favorable than Whitehawk Therapeutics.

Profitability

This table compares iBio and Whitehawk Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-40.66%	-35.78%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Summary

iBio beats Whitehawk Therapeutics on 9 of the 14 factors compared between the two stocks.

About iBio

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.